Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
SYN Synthetic Biologics, Inc. daily Stock Chart
SYN [NYSE]
Synthetic Biologics, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E0.16 EPS (ttm)3.89 Insider Own0.11% Shs Outstand13.76M Perf Week-0.42%
Market Cap8.57M Forward P/E0.30 EPS next Y2.08 Insider Trans0.00% Shs Float13.47M Perf Month4.13%
Income14.00M PEG- EPS next Q-0.81 Inst Own20.00% Short Float3.23% Perf Quarter-23.28%
Sales- P/S- EPS this Y98.40% Inst Trans192.77% Short Ratio1.43 Perf Half Y-77.11%
Book/sh-0.93 P/B- EPS next Y145.70% ROA-60.10% Target Price3.63 Perf Year-95.91%
Cash/sh0.69 P/C0.90 EPS next 5Y- ROE203.60% 52W Range0.51 - 15.75 Perf YTD11.20%
Dividend- P/FCF- EPS past 5Y60.70% ROI- 52W High-96.05% Beta2.48
Dividend %- Quick Ratio2.60 Sales past 5Y- Gross Margin- 52W Low22.58% ATR0.04
Employees24 Current Ratio2.60 Sales Q/Q- Oper. Margin- RSI (14)45.98 Volatility4.26% 5.80%
OptionableNo Debt/Eq- EPS Q/Q80.90% Profit Margin- Rel Volume0.23 Prev Close0.64
ShortableYes LT Debt/Eq- EarningsFeb 21 AMC Payout- Avg Volume303.64K Price0.62
Recom1.50 SMA20-3.33% SMA50-2.58% SMA200-82.72% Volume70,065 Change-2.70%
Jan-06-17Reiterated FBR & Co. Outperform $5 → $6
May-06-16Reiterated FBR Capital Outperform $10 → $9
Feb-26-16Initiated FBR Capital Outperform $10
Oct-13-15Initiated RBC Capital Mkts Outperform $8
Mar-16-15Downgrade Maxim Group Buy → Hold $3
Mar-02-15Reiterated Maxim Group Buy $6 → $3
Mar-19-14Reiterated Maxim Group Buy $3 → $6
Sep-30-13Initiated Maxim Group Buy $3
Jun-25-13Initiated Ascendiant Capital Markets Buy $2.25
Jan-03-19 07:00AM  Synthetic Biologics Announces First Two Patients Enrolled in Phase 2b Investigator-Sponsored PR Newswire
Dec-18-18 10:38AM  Edited Transcript of SYN earnings conference call or presentation 8-Nov-18 9:30pm GMT Thomson Reuters StreetEvents
Dec-04-18 12:00PM  Orchestra BioMed Appoints C. Evan Ballantyne as Chief Financial Officer GlobeNewswire
Nov-27-18 08:20AM  Report: Exploring Fundamental Drivers Behind Synthetic Biologics, Plexus, TG Therapeutics, Hortonworks, NorthWestern, and Archer Daniels Midland New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Nov-22-18 09:10AM  New Trends in Healthcare Push Stocks Higher: 5 Picks Zacks
Nov-21-18 09:25AM  New Healthcare Trends Could Push Sector Stocks Higher ACCESSWIRE +5.88%
07:00AM  Synthetic Biologics Announces Positive Outcome of End-of-Phase 2 Meeting with FDA on SYN-004 (ribaxamase) Development PR Newswire
Nov-08-18 06:02PM  Synthetic Biologics: 3Q Earnings Snapshot Associated Press
04:10PM  Synthetic Biologics Reports Third Quarter 2018 Operational Highlights and Financial Results PR Newswire
Oct-30-18 04:30PM  Synthetic Biologics to Report Third Quarter 2018 Operational Highlights and Financial Results on November 8, 2018 PR Newswire
Oct-18-18 08:40AM  Does Synthetic Biologics Inc (NYSEMKT:SYN) Have A High Beta? Simply Wall St.
Oct-15-18 01:30PM  Synthetic Biologics Announces Closing of $18,639,000 Public Offering PR Newswire
Oct-12-18 07:35AM  Factors of Influence in 2018, Key Indicators and Opportunity within Hyatt Hotels, E.W. Scripps, Cardtronics, Lincoln National, Synthetic Biologics, and Herc New Research Emphasizes Economic Growth GlobeNewswire
Oct-11-18 09:07AM  Synthetic Biologics Prices $18,000,000 Public Offering PR Newswire -38.22%
Sep-30-18 09:26AM  Who Are The Major Shareholders Of Synthetic Biologics Inc (NYSEMKT:SYN)? Simply Wall St.
Sep-06-18 07:00AM  Synthetic Biologics Announces Agreement with Cedars-Sinai Medical Center for an Investigator-Sponsored Clinical Study of SYN-010, for the Treatment of IBS-C PR Newswire
Aug-30-18 04:10PM  Synthetic Biologics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference PR Newswire -5.63%
Aug-23-18 09:50PM  Edited Transcript of SYN earnings conference call or presentation 8-Aug-18 8:30pm GMT Thomson Reuters StreetEvents -7.46%
Aug-17-18 02:32PM  What Goes Through The Mind of A Trader When Taking A Position? Benzinga +7.84%
Aug-13-18 07:55AM  Consolidated Research: 2018 Summary Expectations for Fulton Financial, Leidos, Principal Financial Group, Quanta Services, Synthetic Biologics, and Sterling Fundamental Analysis, Key Performance Indications GlobeNewswire -18.62%
Aug-08-18 05:31PM  Synthetic Biologics: 2Q Earnings Snapshot Associated Press
04:10PM  Synthetic Biologics Reports Second Quarter 2018 Operational Highlights and Financial Results PR Newswire
02:30PM  Synthetic Biologics, Inc. to Host Earnings Call ACCESSWIRE
12:27PM  Is Now The Time To Bet On The Healthcare Sector And Synthetic Biologics Inc (NYSEMKT:SYN)? Simply Wall St.
Aug-01-18 05:05PM  Synthetic Biologics Announces Reverse Stock Split PR Newswire +9.67%
Jul-31-18 07:00AM  Synthetic Biologics to Report Second Quarter 2018 Operational Highlights and Financial Results on August 8, 2018 PR Newswire
Jun-20-18 07:50AM  Stock Performance Review on Sesen Bio and Three Other Biotech ACCESSWIRE
May-22-18 07:00AM  Synthetic Biologics Announces Acceptance of Compliance Plan by NYSE American PR Newswire
May-21-18 07:25AM  Stock Performance Review on Tesaro and Three Other Biotech Industry ACCESSWIRE
May-14-18 11:52AM  Edited Transcript of SYN earnings conference call or presentation 8-May-18 8:30pm GMT Thomson Reuters StreetEvents
07:40AM  Report: Developing Opportunities within Crown, American Equity Investment Life Holding, Acco Brands, Synthetic Biologics, Universal Display, and Lamb Weston Future Expectations, Projections Moving into 2018 GlobeNewswire
May-09-18 07:48AM  Benzinga's Daily Biotech Pulse: Transenterix Rises, Mylan Earnings, Deutsche Bank Conference Underway Benzinga +11.96%
05:11AM  Synthetic Biologics: 1Q Earnings Snapshot Associated Press
May-08-18 04:05PM  Synthetic Biologics Reports First Quarter 2018 Operational Highlights and Financial Results PR Newswire
Apr-26-18 07:00AM  Synthetic Biologics to Report First Quarter 2018 Operational Highlights and Financial Results on May 8, 2018 PR Newswire +9.42%
Apr-23-18 07:00AM  Synthetic Biologics Provides Update on Development of SYN-004 (ribaxamase), for the Prevention of C. difficile Infection PR Newswire -30.33%
Mar-09-18 08:25AM  Report: Exploring Fundamental Drivers Behind EOG Resources, Alteryx, Synthetic Biologics, Extreme Networks, Knight-Swift Transportation Holdings Inc., and Select Medical New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Mar-07-18 04:10PM  Synthetic Biologics Reports on NYSE American Noncompliance Notice and Compliance Plan PR Newswire +25.75%
Feb-22-18 08:21PM  Edited Transcript of SYN earnings conference call or presentation 22-Feb-18 1:30pm GMT Thomson Reuters StreetEvents -10.17%
06:47AM  Synthetic Biologics Reports 2017 Year End Operational Highlights and Financial Results PR Newswire
06:20AM  Synthetic Biologics, Inc. to Host Earnings Call ACCESSWIRE
Feb-15-18 04:10PM  Synthetic Biologics to Report 2017 Year End Operational Highlights and Financial Results on February 22, 2018 PR Newswire -5.08%
Jan-02-18 04:30PM  Synthetic Biologics to Present at the Biotech Showcase 2018 Conference PR Newswire
Dec-05-17 08:00AM  Synthetic Biologics Announces Management Changes PR Newswire
Nov-20-17 08:30AM  ImmunoPrecise Realigns Senior Management CNW Group
Nov-15-17 07:40AM  New Research Coverage Highlights Synthetic Biologics, ReShape Lifesciences, Estée Lauder, Old Republic International, Vulcan Materials, and Taylor Morrison Home Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Nov-02-17 06:44PM  Edited Transcript of SYN earnings conference call or presentation 1-Nov-17 8:30pm GMT Thomson Reuters StreetEvents -11.76%
Nov-01-17 06:37PM  Synthetic Biologics reports 3Q loss Associated Press -5.21%
04:10PM  Synthetic Biologics Reports Third Quarter 2017 Operational Highlights and Financial Results PR Newswire
12:10PM  Synthetic Biologics, Inc. to Host Earnings Call ACCESSWIRE
Oct-25-17 07:00AM  Synthetic Biologics to Report Third Quarter 2017 Operational Highlights and Financial Results on November 1, 2017 PR Newswire
Sep-18-17 08:31AM  Synthetic Biologics (SYN) in Focus: Stock Moves 7.7% Higher Zacks +10.34%
08:20AM  Today's Research Reports on Stocks to Watch: Synthetic Biologics and Microbot Medical ACCESSWIRE
Sep-12-17 07:00AM  Synthetic Biologics Announces Closing of $12 Million Convertible Preferred Stock Financing PR Newswire -5.62%
Sep-06-17 07:30AM  Synthetic Biologics, Inc. Provides Company Overview and Update on Clinical Development in New SNNLive Video Interview with StockNewsNow.com ACCESSWIRE
Aug-29-17 07:00AM  Synthetic Biologics Announces Participation at the 19th Annual Rodman & Renshaw Global Investment Conference in New York City September 10-12, 2017 PR Newswire +11.81%
Aug-21-17 04:05AM  Edited Transcript of SYN earnings conference call or presentation 3-Aug-17 12:30pm GMT Thomson Reuters StreetEvents
Aug-09-17 10:08AM  Zacks.com featured highlights: Stoneridge, Synthetic Biologics, IRadimed Corporation, Syntel and AXT Zacks -10.30%
Aug-08-17 08:40AM  5 Cheap Breakout Stocks Offering Strong Returns Zacks
Aug-03-17 08:34AM  Synthetic Biologics reports 2Q loss Associated Press +6.60%
07:00AM  Synthetic Biologics Reports Second Quarter 2017 Operational Highlights and Financial Results PR Newswire
Jul-27-17 07:00AM  Synthetic Biologics to Report Second Quarter 2017 Operational Highlights and Financial Results on August 3, 2017 PR Newswire
Jun-27-17 07:00AM  Synthetic Biologics Announces Allowance of Key U.S. Patent Covering SYN-010 Intended for the Novel Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) PR Newswire
May-26-17 07:13AM  Can The Uptrend Continue for Synthetic Biologics (SYN)? Zacks
May-24-17 08:00AM  Today's Research Reports on Stocks to Watch: Quantum Corporation and Synthetic Biologics Accesswire
May-12-17 08:15AM  Blog Coverage: Synthetic Biologics Wins Breakthrough Therapy Designation for its Clostridium Difficile Infection Candidate Accesswire -5.50%
May-11-17 03:31PM  Edited Transcript of SYN earnings conference call or presentation 4-May-17 8:30pm GMT Thomson Reuters StreetEvents +28.53%
07:00AM  SYN-004 (Ribaxamase) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Prevention of Clostridium difficile Infection PR Newswire
May-04-17 06:40PM  Synthetic Biologics reports 1Q loss Associated Press
04:05PM  Synthetic Biologics Reports First Quarter 2017 Operational Highlights and Financial Results PR Newswire
Apr-26-17 04:05PM  Synthetic Biologics to Report First Quarter 2017 Operational Highlights and Financial Results on May 4, 2017 PR Newswire +6.36%
Mar-15-17 05:40PM  Forget Gilead, Buy These Small-Cap Biotech Stocks Instead
Mar-08-17 01:04PM  SYNTHETIC BIOLOGICS, INC. Financials
Mar-07-17 07:00AM  Synthetic Biologics to Present at the 29th Annual ROTH Conference PR Newswire
Mar-02-17 05:31PM  Synthetic Biologics reports 4Q loss Associated Press
04:15PM  SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:05PM  Synthetic Biologics Reports 2016 Year End Operational Highlights and Financial Results PR Newswire
Feb-21-17 04:05PM  Synthetic Biologics to Report 2016 Year End Operational Highlights and Financial Results on March 2, 2017 PR Newswire
Feb-13-17 03:04PM  SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
Feb-03-17 07:00AM  Synthetic Biologics to Present at the 2017 BIO CEO & Investor Conference PR Newswire
Jan-19-17 06:04AM  SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Prin
Jan-18-17 04:05PM  Synthetic Biologics Confirms Key Features of Pivotal Phase 2b/3 Trial of SYN-010 Pursuant to Consultations with FDA PR Newswire
Jan-09-17 07:03AM  SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Jan-06-17 10:45AM  Synthetic Biologics C. Difficile Drug Trial Succeeds Investopedia
10:45AM  Synthetic Biologics C. Difficile Drug Trial Succeeds at Investopedia
Jan-05-17 08:15AM  Synthetic Biologics' C. difficile mid-stage study meets main goal Reuters
07:22AM  Synthetic Biologics' C. difficile mid-stage study meets main goal
07:06AM  SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
06:58AM  Synthetic Biologics' SYN-004 (ribaxamase) Achieves Primary Endpoint in Phase 2b Trial for C. difficile Infection (CDI) PR Newswire
Jan-03-17 06:58AM  Synthetic Biologics to Present at the Biotech Showcase 2017 Conference PR Newswire
Dec-13-16 06:58AM  Synthetic Biologics Announces Granting of U.S. Composition of Matter Patent for SYN-005, Designed for the Treatment and Prevention of Pertussis (Whooping Cough) PR Newswire
Dec-02-16 05:02PM  SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Change in Directors or Prin
Dec-01-16 07:00AM  Synthetic Biologics Announces Participation in Two Upcoming Investor Conferences PR Newswire
Nov-19-16 10:15AM  4 Companies That Destroyed Shareholders Last Week at 24/7 Wall St.
Nov-18-16 11:43AM  Synthetic Biologics Announces Closing of Public Offering of Common Stock and Warrants PR Newswire
Nov-15-16 05:13PM  SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Sta
04:04PM  Nokia, Teva Plunge into Tuesdays 52-Week Low Club at 24/7 Wall St.
12:25PM  Synthetic Biologics Prices Secondary Offering
09:08AM  Synthetic Biologics Announces Pricing of Public Offering of Common Stock and Warrants PR Newswire
Nov-14-16 04:05PM  Synthetic Biologics Announces Commencement of Public Offering of Common Stock and Warrants PR Newswire
Synthetic Biologics, Inc., a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C. difficile infection, overgrowth of pathogenic organisms, and the emergence of antimicrobial resistance; and SYN-010 which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The company's preclinical products include an oral formulation of the enzyme intestinal alkaline phosphatase to treat local GI disorders and systemic diseases; monoclonal antibody therapies for the prevention and treatment of pertussis; and novel discovery stage biotherapeutics for the treatment of phenylketonuria. Synthetic Biologics, Inc. has collaborations with Intrexon Corporation, The University of Texas at Austin, and Cedars-Sinai Medical Center. The company was formerly known as Adeona Pharmaceuticals, Inc. and changed its name to Synthetic Biologics, Inc. in February 2012. Synthetic Biologics, Inc. was founded in 2001 and is headquartered in Rockville, Maryland.
open in yahoo | open in reuters | open in google